Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

72.62 USD -2.00 (-2.68%)
Official Closing Price Updated: 7:59 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Merck Animal Health Completes Acquisition of Poultry Sense Limited
Merck Animal Health Completes Acquisition of Poultry Sense Limited 
From Business Wire News Releases
SHAREHOLDER ALERT: WeissLaw LLP Investigates Pandion Therapeutics, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pandion Therapeutics, Inc. ("Pandion" or the "Company") (NASDAQ: PAND) in... 
From PR Newswire
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout
From GlobeNewswire News Releases
PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
Merck to Acquire Pandion Therapeutics
Merck to Acquire Pandion Therapeutics 
From Business Wire News Releases
Merck to Present at the Cowen 41st Annual Health Care Conference
Merck to Present at the Cowen 41st Annual Health Care Conference 
From Business Wire News Releases
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis
Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA Crossed Superiority Boundary of Invasive Disease-Free Survival vs. Placebo 
From Business Wire News Releases
BioSig Appoints Brenda Castrodad to Lead Human Resources
Seasoned medtech executive to scale up the Company’s organizational development upon the increase in demand for the evaluative installations of the PURE EP System™ 
From GlobeNewswire News Releases
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced
KEYTRUDA Plus LENVIMA Demonstrated Superior PFS and OS Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma 
From Business Wire News Releases
Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results
Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results 
From Business Wire News Releases
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman
Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman 
From Business Wire News Releases
Merck Named to FORTUNE's List of World's Most Admired Companies
Tags Responsible Business & Employee Engagement Merck Corporate Social Responsibility
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Dr. Stephen Mayo Elected to Merck Board of Directors
Dr. Stephen Mayo Elected to Merck Board of Directors 
From Business Wire News Releases
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma 
From Business Wire News Releases
Merck Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
Tags LGBTQ Workplace Inclusion Awards, Ratings & Rankings
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic N
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA Plus Ipilimumab Versus KEYTRUDA Monotherapy in Metastatic NSCLC 
From Business Wire News Releases
Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US
Tags Sustainable Development Goals Safer Childbirth Cities merck for mothers
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US
Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity in the US 
From Business Wire News Releases
Merck Announces Second-Quarter 2021 Dividend
Merck Announces Second-Quarter 2021 Dividend 
From Business Wire News Releases
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 
From Business Wire News Releases
European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal
European Commission Approves KEYTRUDA as First-Line Treatment in Adult Patients With Metastatic MSI-H or dMMR Colorectal Cancer 
From Business Wire News Releases
Thinking about trading options or stock in Niu Technologies, Regeneron Pharmaceuticals, General Electric, Merck, or Axon Enterprise?
InvestorsObserver issues critical PriceWatch Alerts for NIU, REGN, GE, MRK, and AAXN. 
From PR Newswire
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates 
From Business Wire News Releases
Merck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge
From PR Newswire
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) 
From Business Wire News Releases
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
José M. Vega, M.D. joins Moderna as Chief Safety Officer. 
From Business Wire News Releases
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
US FDA Accepts for Priority Review the Biologics License Application for V114 for Use in Adults 18 Years of Age and Older 
From Business Wire News Releases
Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4
Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account